Amino acid transporters in cancer and their relevance to “glutamine addiction”: novel targets for the design of a new class of anticancer drugs

YD Bhutia, E Babu, S Ramachandran, V Ganapathy - Cancer research, 2015 - AACR
Cancer research, 2015AACR
Tumor cells have an increased demand for amino acids because of their rapid proliferation
rate. In addition to their need in protein synthesis, several amino acids have other roles in
supporting cancer growth. There are approximately two-dozen amino acid transporters in
humans, and tumor cells must upregulate one or more of these transporters to satisfy their
demand for amino acids. If the transporters that specifically serve this purpose in tumor cells
are identified, they can be targeted for the development of a brand new class of anticancer …
Abstract
Tumor cells have an increased demand for amino acids because of their rapid proliferation rate. In addition to their need in protein synthesis, several amino acids have other roles in supporting cancer growth. There are approximately two-dozen amino acid transporters in humans, and tumor cells must upregulate one or more of these transporters to satisfy their demand for amino acids. If the transporters that specifically serve this purpose in tumor cells are identified, they can be targeted for the development of a brand new class of anticancer drugs; the logical basis of such a strategy would be to starve the tumor cells of an important class of nutrients. To date, four amino acid transporters have been found to be expressed at high levels in cancer: SLC1A5, SLC7A5, SLC7A11, and SLC6A14. Their induction occurs in a cancer type–specific manner with a direct or indirect involvement of the oncogene c-Myc. Further, these transporters are functionally coupled, thus maximizing their ability to promote cancer growth and chemoresistance. Progress has been made in preclinical studies, exploiting these transporters as drug targets in cancer therapy. These transporters also show promise in development of new tumor-imaging probes and in tumor-specific delivery of appropriately designed chemotherapeutic agents. Cancer Res; 75(9); 1782–8. ©2015 AACR.
AACR